Desvenlafaxine

Generic Name: Desvenlafaxine

Brand Names: Pristiq

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₅NO_₂

CAS Number: 93413-62-8

Unique Ingredient Identifier: NG99554ANW

Background: Desvenlafaxine (O-desmethylvenlafaxine) is the 0-demetyhlated active metabolite of venlafaxine. Like its parent drug, desvenlafaxine is also an antidepressant belonging to the class of serotonin-norepinephrine reuptake inhibitor (SNRI) class. It was approved by the FDA in 2008 for the treatment of adults with major depressive disorder (MDD).
...

Indication: Desvenlafaxine is indicated for the treatment of major depressive disorder in adults. It has also been used off-label to treat hot flashes in menopausal women.

Associated Conditions: Hot Flashes, Major Depressive Disorder (MDD)

Associated Therapies: -

Clinical Trials

Prediction of Antidepressant Treatment Response Using Machine Learning Classification Analysis

Phase 4

Conditions: Major Depressive Disorder

Interventions: Drug: Desvenlafaxine
Drug: Placebo

First Posted Date: 2015-01-05

Last Posted Date: 2015-01-05

Lead Sponsor: University of Calgary

Target Recruit Count: 61

Registration Number: NCT02330679

Locations: 🇨🇦
University of Calgary, TRW Building, Foothills Hospital Campus, Calgary, Alberta, Canada
🇨🇦
University of Calgary: Foothills Hospital, Calgary, Alberta, Canada

Serotonin-norepinephrine Reuptake Inhibitors and Acute Kidney Injury

Completed

Conditions: Acute Kidney Injury
Depression

Interventions: Drug: Duloxetine
Drug: Citalopram
Drug: Escitalopram
Drug: Venlafaxine
Drug: Desvenlafaxine
Drug: Fluoxetine
Drug: Fluvoxamine
Drug: Paroxetine
Drug: Sertraline

First Posted Date: 2014-12-19

Last Posted Date: 2016-03-14

Lead Sponsor: Canadian Network for Observational Drug Effect Studies, CNODES

Target Recruit Count: 3255526

Registration Number: NCT02320240

Locations: 🇨🇦
Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada

Desvenlafaxine in Opioid-Dependent Patients

Phase 4

Completed

Conditions: Depression
Opioid Dependence
Methadone Treatment

Interventions: Drug: Desvenlafaxine

First Posted Date: 2014-07-25

Last Posted Date: 2020-10-23

Lead Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)

Target Recruit Count: 18

Registration Number: NCT02200406

Locations: 🇨🇦
Centre de recherche du Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada

Safety, Tolerability and Pharmacokinetics Study of LY03005

Phase 1

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: LY03005
Drug: Pristiq
Drug: Placebo
Other: Meal

First Posted Date: 2014-02-05

Last Posted Date: 2014-11-10

Lead Sponsor: Luye Pharma Group Ltd.

Target Recruit Count: 88

Registration Number: NCT02055300

Locations: 🇺🇸
Medpace, Cincinnati, Ohio, United States

Efficacy of SNRI Treatment on Prefrontality in Patients With GAD and Other Comorbities

Phase 4

Completed

Conditions: Generalized Anxiety Disorder

Interventions: Drug: Desvenlafaxine

First Posted Date: 2013-11-03

Last Posted Date: 2020-10-23

Lead Sponsor: START Clinic for Mood and Anxiety Disorders

Target Recruit Count: 29

Registration Number: NCT01975480

Locations: 🇨🇦
START Clinic for Mood and Anxiety Disorders, Toronto, Ontario, Canada

Desvenlafaxine Monotherapy in Dysthymia

Not Applicable

Completed

Conditions: Dysthymic Disorder

Interventions: Drug: Desvenlafaxine

First Posted Date: 2013-09-24

Last Posted Date: 2014-11-07

Lead Sponsor: Centre for Addiction and Mental Health

Target Recruit Count: 30

Registration Number: NCT01948895

Locations: 🇨🇦
Centre for Addiction and Mental Health, Toronto, Ontario, Canada
🇨🇦
Medical Research Associates, Mississauga, Ontario, Canada

Omega 3 FA Supplements as Augmentation in the Treatment of Depression

Phase 2

Terminated

Conditions: Major Depression
Cancer
Diabetes
Cardiovascular Diseases

Interventions: Drug: Desvenlafaxine
Dietary Supplement: Omega 3 Fatty acids
Drug: Placebo (for Omega 3 fatty acid supplement)

First Posted Date: 2013-03-04

Last Posted Date: 2017-12-27

Lead Sponsor: UConn Health

Target Recruit Count: 6

Registration Number: NCT01803711

Locations: 🇺🇸
University of Connecticut Health Center, Farmington, Connecticut, United States

Desvenlafaxine vs. Placebo Treatment of Chronic Depression

Phase 4

Completed

Conditions: Dysthymic Disorder
Dysthymia
Chronic Depressive Disorder

Interventions: Drug: Placebo
Drug: Desvenlafaxine

First Posted Date: 2012-02-22

Last Posted Date: 2017-09-11

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 59

Registration Number: NCT01537068

Locations: 🇺🇸
New York State Psychiatric Institute/3 Columbus Circle Midtown, New York, New York, United States
🇺🇸
Depression Evaluation Service (DES), New York State Psychiatric Institute, Columbia University Department of Psychiatry, New York, New York, United States

Functional Outcome in Postpartum Depression in Women Treated With Desvenlafaxine

Phase 3

Completed

Conditions: Depression

Interventions: Drug: Desvenlafaxine

First Posted Date: 2012-02-07

Last Posted Date: 2015-01-28

Lead Sponsor: BC Women's Hospital & Health Centre

Target Recruit Count: 25

Registration Number: NCT01527786

Locations: 🇨🇦
BC Women's Hospital, Vancouver, British Columbia, Canada

Effect of Antidepressants on White Matter Structure

Phase 4

Conditions: Major Depression

First Posted Date: 2011-12-15

Last Posted Date: 2011-12-15

Lead Sponsor: Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal

Target Recruit Count: 40

Registration Number: NCT01492621

Locations: 🇨🇦
Centre de Recherche Fernand-Seguin, Montreal, Quebec, Canada

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy